- freely available
Ionic Channels as Targets for Drug Design: A Review on Computational Methods
AbstractIon channels are involved in a broad range of physiological and pathological processes. The implications of ion channels in a variety of diseases, including diabetes, epilepsy, hypertension, cancer and even chronic pain, have signaled them as pivotal drug targets. Thus far, drugs targeting ion channels were developed without detailed knowledge of the molecular interactions between the lead compounds and the target channels. In recent years, however, the emergence of high-resolution structures for a plethora of ion channels paves the way for computer-assisted drug design. Currently, available functional and structural data provide an attractive platform to generate models that combine substrate-based and protein-based approaches. In silico approaches include homology modeling, quantitative structure-activity relationships, virtual ligand screening, similarity and pharmacophore searching, data mining, and data analysis tools. These strategies have been frequently used in the discovery and optimization of novel molecules with enhanced affinity and specificity for the selected therapeutic targets. In this review we summarize recent applications of in silico methods that are being used for the development of ion channel drugs.
Share & Cite This Article
Export to BibTeX | EndNote
MDPI and ACS Style
Fernández-Ballester, G.; Fernández-Carvajal, A.; González-Ros, J.M.; Ferrer-Montiel, A. Ionic Channels as Targets for Drug Design: A Review on Computational Methods. Pharmaceutics 2011, 3, 932-953.View more citation formats
Fernández-Ballester G, Fernández-Carvajal A, González-Ros JM, Ferrer-Montiel A. Ionic Channels as Targets for Drug Design: A Review on Computational Methods. Pharmaceutics. 2011; 3(4):932-953.Chicago/Turabian Style
Fernández-Ballester, Gregorio; Fernández-Carvajal, Asia; González-Ros, José Manuel; Ferrer-Montiel, Antonio. 2011. "Ionic Channels as Targets for Drug Design: A Review on Computational Methods." Pharmaceutics 3, no. 4: 932-953.